[go: up one dir, main page]

PL3810128T3 - Kompozycje do leczenia i/lub zapobiegania chorobom związanym z agregacją białek - Google Patents

Kompozycje do leczenia i/lub zapobiegania chorobom związanym z agregacją białek

Info

Publication number
PL3810128T3
PL3810128T3 PL19730826.5T PL19730826T PL3810128T3 PL 3810128 T3 PL3810128 T3 PL 3810128T3 PL 19730826 T PL19730826 T PL 19730826T PL 3810128 T3 PL3810128 T3 PL 3810128T3
Authority
PL
Poland
Prior art keywords
prevention
compositions
treatment
protein aggregation
aggregation diseases
Prior art date
Application number
PL19730826.5T
Other languages
English (en)
Inventor
Manuel J. MUÑOZ
Ángel M. CARRIÓN
Mercedes M. PÉREZ-JIMÉNEZ
Original Assignee
Universidad Pablo De Olavide
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Pablo De Olavide filed Critical Universidad Pablo De Olavide
Publication of PL3810128T3 publication Critical patent/PL3810128T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37Coumarins, e.g. psoralen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
PL19730826.5T 2018-06-19 2019-06-19 Kompozycje do leczenia i/lub zapobiegania chorobom związanym z agregacją białek PL3810128T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382439 2018-06-19
PCT/EP2019/066271 WO2019243453A1 (en) 2018-06-19 2019-06-19 Compositions for treating and/or preventing protein-aggregation diseases

Publications (1)

Publication Number Publication Date
PL3810128T3 true PL3810128T3 (pl) 2023-01-30

Family

ID=62716030

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19730826.5T PL3810128T3 (pl) 2018-06-19 2019-06-19 Kompozycje do leczenia i/lub zapobiegania chorobom związanym z agregacją białek

Country Status (15)

Country Link
US (1) US20210251953A1 (pl)
EP (2) EP4094754B1 (pl)
JP (2) JP2021528442A (pl)
CN (2) CN112601521A (pl)
AU (1) AU2019291061B2 (pl)
BR (1) BR112020026066A2 (pl)
CA (1) CA3103834A1 (pl)
DK (1) DK3810128T3 (pl)
ES (2) ES3044215T3 (pl)
MX (1) MX2020014070A (pl)
PL (1) PL3810128T3 (pl)
PT (1) PT3810128T (pl)
RS (1) RS67299B1 (pl)
SM (1) SMT202500382T1 (pl)
WO (1) WO2019243453A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
PL3810128T3 (pl) * 2018-06-19 2023-01-30 Universidad Pablo De Olavide Kompozycje do leczenia i/lub zapobiegania chorobom związanym z agregacją białek
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
EP3988096A1 (en) 2020-10-26 2022-04-27 Universidad Pablo de Olavide OTRI Sulfated c19 steroid hormones to treat and/or prevent proteotoxicity in protein-aggregation diseases
CN112552272B (zh) * 2020-12-22 2023-06-27 四川大学 香豆素类化合物及其制备方法和应用、药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9603325D0 (en) 1996-02-16 1996-04-17 Imperial College A compound
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
JP4320089B2 (ja) * 1999-07-06 2009-08-26 あすか製薬株式会社 フェニルスルファメート誘導体
DK1311272T3 (da) * 2000-03-03 2007-02-26 Eisai R&D Man Co Ltd Hidtil ukendte fremgangsmåder hvor der anvendes cholinesteraseinhibitorer
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
GB0511190D0 (en) * 2005-06-01 2005-07-06 Sterix Ltd Use
ES2514140B1 (es) * 2013-03-26 2015-08-03 Universidad Pablo De Olavide Uso del inhibidor de sulfatasas esteroideas STX64 para el tratamiento del envejecimiento
CN107249580A (zh) * 2014-12-05 2017-10-13 An2H探索有限公司 帕金连接酶活化方法和组合物
JP2018532748A (ja) 2015-10-30 2018-11-08 ウルトラジェニクス ファーマシューティカル インク.Ultragenyx Pharmaceutical Inc. アミロイドーシス治療のための方法及び組成物
US10780094B2 (en) * 2016-07-22 2020-09-22 New York University Use of carbonic anhydrase inhibitors for treatment of neurological and psychiatric disorders
PL3810128T3 (pl) * 2018-06-19 2023-01-30 Universidad Pablo De Olavide Kompozycje do leczenia i/lub zapobiegania chorobom związanym z agregacją białek

Also Published As

Publication number Publication date
AU2019291061B2 (en) 2025-04-10
BR112020026066A2 (pt) 2021-03-23
DK3810128T3 (da) 2022-10-31
CN112601521A (zh) 2021-04-02
ES3044215T3 (en) 2025-11-26
EP4094754A1 (en) 2022-11-30
JP2021528442A (ja) 2021-10-21
JP2024059803A (ja) 2024-05-01
WO2019243453A1 (en) 2019-12-26
AU2019291061A1 (en) 2021-02-04
ES2931815T3 (es) 2023-01-02
CN118845759A (zh) 2024-10-29
CA3103834A1 (en) 2019-12-26
PT3810128T (pt) 2022-11-09
US20210251953A1 (en) 2021-08-19
SMT202500382T1 (it) 2025-11-10
EP4094754C0 (en) 2025-08-06
EP3810128A1 (en) 2021-04-28
EP3810128B1 (en) 2022-08-03
RS67299B1 (sr) 2025-11-28
EP4094754B1 (en) 2025-08-06
MX2020014070A (es) 2021-05-27

Similar Documents

Publication Publication Date Title
IL280710A (en) Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy
PL3810128T3 (pl) Kompozycje do leczenia i/lub zapobiegania chorobom związanym z agregacją białek
EP3826666A4 (en) COMPOSITIONS AND METHODS OF TREATING DISEASES ASSOCIATED WITH NRP2
EP3784260A4 (en) Compositions for the treatment of skin conditions
IL287796A (en) Preparations and methods for the treatment of diseases mediated by ATPase
EP3790563A4 (en) Compositions for the treatment of skin conditions
IL269158A (en) Compositions and methods for treating inflammatory diseases
EP3810124A4 (en) COMPOSITION INTENDED FOR THE TREATMENT OF DRY EYE SYNDROME AND MEIBOMITIS
PL3500287T3 (pl) Kompozycja zawierająca samoorganizujące się peptydy do stosowania do leczenia zapalenia przyzębia i/lub zapalenia tkanek okołowszczepowych
EP3827837A4 (en) Composition for preventing or treating immune-related diseases
EP3523281A4 (en) AUTOPHAGIC RIVER AND PHOSPHOLIPASE D ACTIVATORS AND PROTEIN UNIT CLEANING INCLUDING DEW AND TREATMENT OF PROTEINOPATHIA
EP3830196A4 (en) SURFACE TREATMENT COMPOSITIONS AND METHODS
EP3818085A4 (en) COMPOSITIONS AND THEIR USES FOR TREATING A DISEASE OR CONDITION
EP3398437A4 (en) PESTICIDE COMPOSITION CONTAINING METCONAZOLE FOR PREVENTING AND TREATING FUSARIOSIS OF PPE AND ITS APPLICATION
EP3582768A4 (en) CANNABINOID FORMULATIONS FOR THE TREATMENT OF DERMATITIS AND INFLAMMATORY SKIN DISEASES
EP3728279A4 (en) GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS
IT201700085412A1 (it) Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare
EP3592377A4 (en) TISSUE KALLICREIN DOSAGE FORMS 1
EP3775261A4 (en) TARGET BOND FRACTION COMPOSITIONS AND METHODS OF USE
EP3719032A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF HAIR LOSS
EP3262065C0 (en) METHODS AND COMPOSITIONS FOR TREATING DYSTROGLYCANOPATHIES
EP3632430A4 (en) Agent for preventing or treating spinocerebellar ataxia
EP3576799A4 (en) OPHTHALMIC COMPOSITIONS FOR THERAPEUTIC AND PROPHYLACTIC USE
EP3570825A4 (en) COMPOSITIONS FOR USE IN THE TREATMENT OF INFLAMMATORY INTESTINAL DISEASE AND INTESTINAL COLITIS
EP3840745A4 (en) METHODS AND COMPOSITIONS FOR MEDICINES FOR TREATING OPHTHALMIC DISEASES